ライフサイエンスコーパス: molecular target

1 nic middle ear inflammation, and a potential molecular target.

2 althy tissues that express low levels of the molecular target.

3 unambiguously identified ATP synthase as its molecular target.

4 maximize the clinical potential of EGFR as a molecular target.

5 cell biology data point to Dyrk1a as the key molecular target.

6 overy of bioactive small molecules and their molecular targets.

7 iation studies (GWASs) to identify potential molecular targets.

8 , despite genomic sequencing, lack effective molecular targets.

9 is unique alkaloid across panels of discrete molecular targets.

10 ely used in bioanalytical methods to capture molecular targets.

11 btype of cancer owing to a lack of validated molecular targets.

12 effects off their intended cancer tissue or molecular targets.

13 system result from the modulation of several molecular targets.

14 ove drug potency towards inhibition of their molecular targets.

15 of unrecognized cancer-driving hotspots and molecular targets.

16 o obtain a SERS signal on cell-type specific molecular targets.

17 high-throughput and virtual screens against molecular targets.

18 ion in various forms of RP, and identify new molecular targets.

19 nd compare the findings across the different molecular targets.

20 the energy balance in mice through multiple molecular targets.

21 pectroscopy allows the detection of multiple molecular targets.

22 tremendous range of previously inaccessible molecular targets.

23 micarbazones result in marked alterations in molecular targeting.

24 yl function groups on the ICG-NPs for future molecular targeting.

25 ging with high sensitivity and potential for molecular targeting.

26 zed the management of advanced RCC; 10 novel molecular targeted agents and immune checkpoint inhibito

27 B) has merit, especially in combination with molecular targeted agents that inhibit heat shock protei

28 ostic information by specifically locating a molecular target altered in the disease process.

29 depend on the a priori selection of a single molecular target and may detect novel biologically relev

30 y 15% of invasive breast cancers, and is the molecular target and predictive marker of response to an

31 Identification of molecular targets and anti-fibrotic therapies could prov

32 s on genomic profiling of the tumors to find molecular targets and develop specific agents for indivi

33 r (AUD) emphasize the need to identify novel molecular targets and efficiently screen new compounds a

34 e known to regulate organogenesis, but their molecular targets and function in midbrain dopaminergic

35 Here, we have elucidated the molecular targets and function of TRMT1 to uncover the c

36 everal epithelial genes; however, additional molecular targets and functional processes regulated by

37 each TKI interacts with a unique profile of molecular targets and has been associated with a unique

38 ure mechanistic studies to identify specific molecular targets and pathways that may be altered in ac

39 nhancer regions revealed putative oncogenes, molecular targets and pathways; inhibition of these targ

40 led to the identification of cancer-specific molecular targets and potential drugs to confront these

41 cancer PDX models in the discovery of novel molecular targets and predictive biomarkers for personal

42 lead to the identification of specific novel molecular targets and predictive biomarkers for therapy.

43 The molecular targets and the key nodes in genetic networks

44 Several of these new markers, molecular targets, and therapeutic approaches have been

45 They bind their molecular target (antigen) by recognizing a portion of i

46 This molecular target approach may facilitate the in vivo non

47 Representing the enormous success of a molecular targeted approach, natalizumab was the first m

48 the direct optical observation of individual molecular targets ( approximately 5 nm) in a densely pac

49 tumors expressing low levels of the relevant molecular targets are deemed ineligible for such targete

50 microorganisms to higher eukaryotes, but its molecular targets are largely unknown.

51 arget has achieved limited success and novel molecular targets are required.

52 t angiogenesis inhibitors, regardless of the molecular target, are teratogenic when exposed to chicke

53 ies, which act on specific cancer-associated molecular targets, are predominantly inhibitors of oncog

54 be adapted to other cancer cell types and to molecular targets associated with disease progression.

55 d can enable multiplexed imaging of multiple molecular targets at high-resolution coupled with conven

56 nown of the distribution of their respective molecular targets, but crucially also revealed system-wi

57 Molecular targeting by the LKB1 complex depends on subce

58 Cell-based studies have identified several molecular target candidates of manassantin including NF-

59 ed to local availability of its main central molecular target, cannabinoid-1 (CB1) receptors in man.

60 d, with a focused approach to understand the molecular targets, cellular effectors, and receptors.

61 taneously or monovalently to their different molecular targets; coinjection of a cocktail of radiolig

62 h D2 autoreceptors and associated downstream molecular targets converging on GSK-3 and suggest a new

63 he springboard for developing drugs aimed at molecular targets deemed crucial to tumours.

64 er, despite its recognition as a stand-alone molecular target, development of suitable strategies to

65 Our results yielded novel candidate molecular targets driving the development of cardiovascu

66 h RF ablation is possible when combined with molecular-targeted drug delivery systems.

67 age, an inherent challenge in the use of any molecular-targeted drug in cancer settings.

68 extension, may have distinct or overlapping molecular targets during both immunity and development.

69 rapeutic approaches suggesting that combined molecular targets (e.g., dual inhibition of IL-1beta and

70 ity and memory retrieval share at least some molecular targets (e.g., recycling alpha-amino-3-hydroxy

71 acromolecular- and cellular-scale effects of molecular targeting (fibronectin, talin, ROCK), includin

72 hat alphaB-crystallin represents a promising molecular target for antimetastatic therapies.

73 The dopamine D3 receptor (D3R) is a molecular target for both first-generation and several r

74 cer cells, indicating that STAT3 is a viable molecular target for cancer therapy.

75 g cancers, and has been prioritized as a key molecular target for cancer therapy.

76 The primary molecular target for clinically used opioids is the mu-o

77 n colon cancer, and that GRM3 is a promising molecular target for colon cancer treatment.

78 ects, making GRM3 an attractive and specific molecular target for colon cancer treatment.

79 Hsp90, our workflow may help identifying the molecular target for compounds found by screening large

80 We propose that AID could be a novel molecular target for controlling antibody-mediated rejec

81 gnaling, suggesting that AIB1 is a potential molecular target for CRC treatment.

82 These properties render Hec1 a promising molecular target for developing therapeutic drugs that e

83 corepressor and identify NCoR as a potential molecular target for development of novel cancer therapi

84 5-HT1BRs putatively represent a molecular target for development of pharmacologic antiag

85 Thus, SIRT2 may be a novel molecular target for diabetes therapy and may thus shed

86 nd their regulatory axis represents a unique molecular target for diagnostic and therapeutic interven

87 Together these results reveal a new molecular target for DMF and show that a clinically appr

88 This renders PIK3CA an attractive molecular target for early detection and personalised th

89 Thus YY1AP1 may serve as a key molecular target for EpCAM(+) AFP(+) HCC subtype.

90 Our findings uncover NALP3 as a molecular target for FBXL2 and suggest that therapeutic

91 -Fluo mimicking the V3 loop of gp120, as the molecular target for fluorescence-quenching binding affi

92 suggest that the PPARgamma pathway is a new molecular target for future preventative strategies for

93 o HD cortical alterations, placing Kal7 as a molecular target for future therapies aimed to restore c

94 ese results establish miR-503 as a promising molecular target for glioblastoma therapy.

95 is associated with acute GVHD and is a novel molecular target for GVHD prevention and treatment.

96 These findings identify TRPA1 as a molecular target for HQ and provide insights into the me

97 eceptor subtype 7 (P2X7R) represents a novel molecular target for imaging neuroinflammation via PET.

98 mechanism in MCC and suggest utility of this molecular target for improved MCC therapy.

99 autoimmunity but also provide an attractive molecular target for intervention strategies of patients

100 Thus, AhR might represent a novel molecular target for manipulation of B cell responses du

101 effective at improving lifespan, provides a molecular target for mitigating locomotor dysfunction in

102 uring viral infection represents a promising molecular target for mitigating viral spread and persist

103 Downregulation of CD20, a molecular target for monoclonal antibodies (mAbs), is a

104 s of NASH and identify it as a potential new molecular target for NASH therapy.

105 M1 muscarinic acetylcholine receptor, a key molecular target for novel cognition enhancers, by using

106 Therefore, an ideal molecular target for novel pharmaceutical intervention w

107 ntly, we propose the Nav1.6 channel as a new molecular target for patients with KCNQ2 encephalopathy,

108 In addition, SERT is a major molecular target for psychostimulants such as cocaine an

109 M(pro) has been recognized as an attractive molecular target for rational anti-CoV drug design.

110 pears to have the potential to form a unique molecular target for small molecule binding and interfer

111 Here we identify a molecular target for the antischistosomal eutomer - (R)-

112 This indicates that CDK2 is a useful molecular target for the chemoprevention and therapy aga

113 Our studies identify TNFR2 in the CNS as a molecular target for the development of remyelinating ag

114 This identifies TNFR2 as a new molecular target for the development of therapeutic agen

115 barrier integrity and that AhR represents a molecular target for the development of therapeutic appr

116 lator of NF-kappaB signaling and a potential molecular target for the MES subtype of glioblastomas.

117 Although EGFR is currently a favorite molecular target for the treatment of these cancers, inh

118 PP1 could constitute an efficient and direct molecular target for therapeutic interventions in Huntin

119 DM2/MDM4 interaction interface as a valuable molecular target for therapeutic reactivation of p53 onc

120 established a novel therapeutic strategy and molecular target for thrombotic diseases, especially for

121 Thus, our data identify EphA2 as a novel molecular target for TNBC.

122 P(C) as a new and potentially more druggable molecular target for treating Alzheimer's disease.

123 FGFR1 in the kidney may provide a new molecular target for treating hypertension.

124 is study suggests that ALOX15 is a potential molecular target for treatment of ALD.

125 progression of SLE and point to a potential molecular target for treatment of autoimmunity.

126 eases and has been identified as a potential molecular target for treatment of neurodegeneration.

127 PPARgamma is the molecular target for type 2 diabetes mellitus (T2DM) the

128 erexpressed in primary ovarian cancers, as a molecular target for visualizing peritoneal metastases f

129 We selected 12 diverse molecular targets for Affimer selection to exemplify the

130 e emerged as diagnostic biomarkers and novel molecular targets for anti-cancer drug therapies.

131 t signaling toward aggregation and (2) novel molecular targets for antiplatelet treatment strategies.

132 gs such as biomarkers for APL and additional molecular targets for arsenic trioxide therapy.

133 Among the potential molecular targets for attaining these unmet therapeutic

134 However, molecular targets for correction of endoplasmic reticulu

135 er potassium (Kir) channels represent viable molecular targets for developing insecticides with new m

136 Together, our results identified molecular targets for developing pro-longevity microbes

137 ce variants to serve as novel biomarkers and molecular targets for developmental therapeutics in aggr

138 The identification of new molecular targets for diagnostic and therapeutic applica

139 a survey of the studies that have suggested molecular targets for drug development for ASD and the s

140 east cancer and currently lacks well-defined molecular targets for effective targeted therapies.

141 m and may lead to the discovery of potential molecular targets for efficient tick control.

142 hanisms of FTD and ALS and suggest promising molecular targets for future therapeutic interventions i

143 l of gene expression may provide a source of molecular targets for glioblastoma radiosensitization.

144 They also identify tissue-specific molecular targets for GM hemorrhage intervention.

145 rtance because it offers numerous innovative molecular targets for limiting kidney injury by blocking

146 s critical for therapeutic activity, because molecular targets for most diseases are located outside

147 These advances include identification of new molecular targets for personalized targeted therapy, val

148 stem cell populations, identifying potential molecular targets for pharmacological radioprotection of

149 (PK) data; protein sequences of ADME-related molecular targets for pre-clinical model species and hum

150 cinomas, highlighting their potential as new molecular targets for prevention or treatment of UVR-ind

151 ically expressed in GABAergic VTA neurons as molecular targets for smoking cessation therapeutics.

152 Moreover, they suggest possible novel molecular targets for the abrogation of tumor microenvir

153 a mechanistic explanation for, and potential molecular targets for the amelioration of, the hyperprol

154 Identifying the molecular targets for the beneficial effects of active s

155 These findings identify novel potential molecular targets for the modulation of venous capacitan

156 Notably, cannabinoid receptors serve as molecular targets for the psychotropic plant-derived can

157 reast tumors and currently possess almost no molecular targets for therapeutic options in this horizo

158 Data identify novel molecular targets for therapeutic strategies aimed at da

159 ould lead to the identification of potential molecular targets for therapeutics against Chlamydia.

160 Molecular targets for therapy are being sought.

161 disease mechanism and identifying potential molecular targets for treatment.

162 ventions at the same time as identifying new molecular targets for treatment.

163 e report a method to screen and identify new molecular targets for tumor-targeted nanomedicine based

164 y EGFR and HIF, both of which are attractive molecular targets for use in combination with immunother

165 for high-risk myelodysplastic syndrome whose molecular target had remained controversial, pointed sin

166 e against blood-stage malaria parasites; its molecular target has been identified as translation elon

167 While clinically effective, its molecular target has remained elusive - although it is k

168 Yet, efforts at molecular targeting have tested small molecules, peptide

169 Many attractive putative molecular targets have failed to produce a significant e

170 DNA aptamers that can bind specific molecular targets have great potential as probes for mic

171 To identify its molecular targets, IL-31-dependent gene expression was d

172 NOTCH signaling has been a molecular target in BTICs, but NOTCH antagonists have de

173 not in reversal reaction and provides a new molecular target in ENL pathogenesis.

174 of aberrant S-nitrosylation in HCC, a novel molecular target in SDH, and a first-in-class therapy to

175 onses and thus represents a unique and novel molecular target in transplant immunology.

176 r immunohistochemistry to evaluate potential molecular targets in human tumor tissue sections.

177 nowledge gap exists in clinically actionable molecular targets in Li-Fraumeni syndrome (LFS), a highl

178 sequencing uncovers novel miR-141-regulated molecular targets in PCa cells including the Rho GTPase

179 animal PET to characterize the expression of molecular targets in the recently reported HD animal mod

180 continuous, real-time monitoring of specific molecular targets in unprocessed clinical samples would

181 ents exhibit tumor-selective expression of a molecular target-in this case, HER2.

182 rain barrier, has been shown to hit multiple molecular targets involved in AD and have beneficial eff

183 Accordingly, the molecular targets involved in formation and physiologica

184 ontinuous, real-time measurement of specific molecular targets (irrespective of their chemical reacti

185 nteraction between the GNPs and the intended molecular target is critical for the development of reli

186 Identifying a molecular target is essential for tumor-targeted nanomed

187 etic requisites of ligand binding toward its molecular target is of paramount relevance in drug desig

188 owering properties in animal models, but its molecular target is unknown, which hinders further drug

189 Molecular targeting is an import strategy to treat advan

190 Identification of molecular targets is important for the intervention and/

191 Potential molecular targets linking RMG/photoreceptor interaction

192 ontribute to tumor radioresistance and their molecular targeting may enhance the effectiveness of rad

193 nase (AMPK), we determined whether AMPK is a molecular target mediating this apoptotic cascade by uti

194 Therefore, relevant molecular targets need to be identified.

195 restingly, knockdown of ATGL, the best-known molecular target of ABHD5, impeded the proliferation and

196 lipoxygenase was discovered as an additional molecular target of ajudazol B.

197 in Rx1 immune signaling and define DNA as a molecular target of an activated NLR.

198 lippase at the IM of mycobacteria and is the molecular target of BM212, a 1,5-diarylpyrrole compound.

199 the Listeria monocytogenes protein PgpH as a molecular target of c-di-AMP.

200 nctional and biophysical analyses reveal the molecular target of disulfiram's tumour-suppressing effe

201 Here we demonstrate the molecular target of DU011, our previously discovered pot

202 the canonical autophagy pathway in DCs as a molecular target of Foxp3+ Treg-mediated suppression tha

203 3-P synthase (EPSPS) gene, which encodes the molecular target of glyphosate.

204 ent identification of cereblon (CRBN) as the molecular target of LEN, the cellular mechanism by which

205 nic acetylcholine receptors (nAChRs) are the molecular target of nicotine.

206 One suggested molecular target of resveratrol is eukaryotic topoisomer

207 ipid-hydrolyzing activity of PLDalpha1, is a molecular target of RGS1.

208 ct interactions with Argonaute-2 (Ago2), the molecular target of siRNAs, is not known.

209 transcription through Smoothened (Smo), the molecular target of the Hh pathway inhibitors used as ca

210 One possible molecular target of thyroid hormone disrupting chemicals

211 petition assays established that the primary molecular target of VR23 was beta2 of the 20S proteasome

212 nt growth phenotype in PCa cells through its molecular targeting of AR and glucocorticoid receptor (G

213 ovalently functionalized with folic acid for molecular targeting of cancer cells.

214 dent malignant progression, and suggest that molecular targeting of p62/Sqstm1 represents a potential

215 Molecular targeting of proteins involved in the endosoma

216 Both pharmacological and molecular targeting of PYK2 attenuated the amplification

217 contains information on immune epitopes--the molecular targets of adaptive immune responses--curated

218 But less is known about specific molecular targets of AGE and its bioactive components, i

219 However, there are numerous molecular targets of alcohol in the cerebellum, and it i

220 This article reviews platelet function, molecular targets of antiplatelet agents, and clinical i

221 plored common variants of genes representing molecular targets of coxibs for association with CAD.

222 We now identify molecular targets of DHI in resistance vasculatures and

223 skin carcinogenesis, identification of novel molecular targets of diagnostic and therapeutic signific

224 ear NPC1L1 or HMGCR, encoding the respective molecular targets of ezetimibe and statins, have previou

225 ory and anti-tumorigenic properties; yet the molecular targets of HNK are not well studied.

226 y require a preexisting understanding of the molecular targets of individual lipid species.

227 Defining the molecular targets of insecticides is crucial for assessi

228 depression of contraction and uncovered the molecular targets of isoflurane and propofol.

229 involving DDX41, STING, and other downstream molecular targets of L. monocytogenes-generated c-di-AMP

230 other genes encoding current or prospective molecular targets of lipid-lowering therapy (ie, HMGCR,

231 cularly SGK1 and EGFR were identified as key molecular targets of metformin.

232 oteomics experiments and identify the direct molecular targets of the asparagusic acid tag.

233 of THDCs exposure in humans, and one of the molecular targets of these chemicals is the hormone tran

234 Screening molecular targets of water-soluble 3'-oxime ethers revea

235 er injures have occurred and help narrow the molecular targets of WldS activity to events within the

236 l strategy and to the selection of CD38 as a molecular target on CLL cells, both consenting efficient

237 Therefore, examining molecular targets on this population of nociceptive fibe

238 However, no such molecular targets or broad spectrum drugs have been iden

239 Discovery of molecular targets or compounds that alter neuronal funct

240 Current assays are molecular target- or cell culture-based platforms.

241 it cannot be readily used to image specific molecular targets quantitatively inside live cells.

242 nomer sequence control confers potential for molecular targeting, recognition and biocatalysis, as we

243 on checkpoint during thymopoiesis, yet their molecular targets remain largely unknown.

244 We show such molecular target remains unchanged across 30 clinical is

245 Downstream molecular targets responsible for AHR-dependent adverse

246 retain biological activity and alkylate the molecular target(s) of Plasmodium falciparum 3D7 parasit

247 However, the molecular target(s) of PZQ remain undefined.

248 t--an armamentarium of drugs and an array of molecular targets--set the stage for precision oncology,

249 sidering the physiological conditions at the molecular target site.

250 Identification of potential molecular targets specific to this population of fibers

251 To enable screening of molecular target-specific molecules for higher nerve con

252 ding the development of novel biomarkers and molecular targeting strategies.

253 ctive for alpha9alpha10 nAChRs vs. all other molecular targets tested, including opioid and GABAB rec

254 for the exploration of the CYGB pathway as a molecular target that can be used to enhance the effecti

255 as served the unifying purpose of defining a molecular target that can limit the structural and funct

256 ator of CaMKII-dependent LTP and therefore a molecular target that controls synaptic plasticity and a

257 via direct LDB1 interaction, is a potential molecular target that could be exploited in LMO2-driven

258 One molecular target that should receive more attention is t

259 Molecular targets that are accessible directly from the

260 of this preclinical model system to identify molecular targets that could be relevant to human therap

261 ies, position us to expand the assortment of molecular targets that could facilitate personalized tre

262 d are the clinical relevance of cellular and molecular targets that have been investigated in experim

263 rocyte cultures as model systems to identify molecular targets that link cell surface GPR17 to oligod

264 to identify the properties of particles and molecular targets that link exposure with specific biolo

265 le complexity of DLBCL and identified unique molecular targets that may be differentially exploited f

266 To identify molecular targets that modify sensitivity to lenalidomid

267 double emulsion are developed for versatile molecular targeted therapeutics and antibody combination

268 provided a framework for the development of molecular targeted therapeutics that are functionally li

269 trials demonstrate the selective efficacy of molecular-targeted therapeutics based on somatic mutatio

270 Molecular targeted therapies are not in routine use and

271 nical trials, STAT3 might be a candidate for molecular targeted therapies of SSc.

272 could form the basis for the development of molecular targeted therapies to improve clinical outcome

273 ng chemotherapy, chemoradiation therapy, and molecular targeted therapies) to assess the modalities t

274 ations confer resistance to conventional and molecular targeted therapies.

275 Molecular targeted therapy has the potential to dramatic

276 rated screens revealed a new pathway for the molecular targeted therapy of HD.

277 s after burn injury and as a novel potential molecular target to improve the clinical outcome of seve

278 ns, and identifies Nav1.6 as a new potential molecular target to reduce excitability in patients with

279 , confocal microscopy, and pharmacologic and molecular targeting to address these gaps in knowledge i

280 om-up and top-down approaches, building from molecular targets to behavioral analyses and vice versa,

281 Approaches and molecular targets to develop future pharmacotherapy targ

282 an be used to observe expression patterns of molecular targets to improve understanding of key biolog

283 , TNF-alpha/TNFR1, RIPK1, RIPK3 and MLKL are molecular targets to limit crystal-induced cytotoxicity,

284 ell lineage specificity and offer additional molecular targets to manipulate MSC-involved tissue repa

285 e function of these cells and identify novel molecular targets to modulate disease progression.

286 Thus, identifying novel molecular targets to prevent and/or mitigate EAC is impe

287 Integration of imaging data across different molecular target types can provide in-depth insight into

288 vo experiments, we provide evidence that the molecular target underlying the thrombolytic effects of

289 activating EGFR, AP2M1, and NUMB and as the molecular targets underlying the antiviral effect of sun

290 DRG) neurons revealed the peptide's putative molecular target (voltage-gated sodium channels) and mec

291 ropose that the secreted AGR2 is a blockable molecular target, which acts as a chaperon-like enhancer

292 mics, we identified pirin as a high affinity molecular target, which was confirmed by SPR and crystal

293 be readily achieved through DNA encoding of molecular targets, which translates the molecular identi

294 ence endomicroscopy provides quick access to molecular targets, while Raman spectroscopy allows the d

295 eta), and the chemokine CXCL8 - as potential molecular targets whose individual or combined inhibitio

296 ey define specific pro- and antiregenerative molecular targets whose regenerative regulation is postp

297 e been previously studied, demonstrations of molecular targeting with such agents in live animals hav

298 gonucleotides capable of binding to specific molecular targets with high affinity and if integrated t

299 The search for a BV molecular target within the parasites identified P. falc

300 s within the nervous system through discrete molecular targets; yet, data from family and twin analys